What's Happening?
CND Life Sciences has been awarded a $3 million grant from the National Institutes of Health (NIH) to study the potential link between essential tremor (ET) and Parkinson's disease (PD). The study will utilize the Syn-One Test, a diagnostic tool that
detects the presence of phosphorylated alpha-synuclein (P-SYN), a protein associated with PD. The three-year multicenter study aims to determine if individuals with ET who test positive for P-SYN are at a higher risk of developing PD. The study will involve approximately 300 participants and will be conducted at 15 sites across the U.S., including Baylor University Medical Center and Beth Israel Deaconess Medical Center.
Why It's Important?
This research could significantly impact the understanding and management of essential tremor and its potential progression to Parkinson's disease. With an estimated seven million people in the U.S. affected by ET, identifying those at risk for PD could lead to earlier interventions and improved treatment strategies. The study's findings may provide valuable insights into the progression of neurodegenerative diseases, potentially leading to the development of novel therapies and more targeted care for patients.
What's Next?
Recruitment and enrollment for the study are expected to begin in December 2025. The research team aims to demonstrate that early identification of P-SYN in ET patients can lead to early intervention and the development of new therapies. The study's outcomes could influence future diagnostic and treatment approaches for neurodegenerative diseases, emphasizing the importance of early detection and targeted care.
Beyond the Headlines
The Syn-One Test has been designated as a Breakthrough Device by the FDA, highlighting its potential to aid in the diagnosis of synucleinopathies. This designation could expedite the development and review of the test, potentially leading to broader clinical adoption and improved patient outcomes.
